Quality control concerns in relation to lamotrigine and their impact.

Gordon B ParkerAndrew Jenner

Published in: Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists (2022)

We failed to identify any intrinsically compromised product in our comparison analyses of the six preparations. We consider alternate explanations for an issue leading to widespread international reporting of distinct side-effects and deaths following brand switching, with analyses of the two problematic preparations supporting a 'faulty' batch explanation.

Keyphrases

quality control
adverse drug
emergency department
clinical evaluation